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Pulmonary Sarcoidosis in a patient with Multiple Sclerosis on Daclizumab 
monotherapy 
 
ABSTRACT 
As new immunomodulatory therapies continue to be licensed for use in Multiple Sclerosis, it 
is important to remain vigilant for new, unexpected associations relating to these medications. 
We highlight this by reporting on a case of a 45-year-old man who developed systemic, non-
specific symptoms following long term use of daclizumab and was subsequently diagnosed 
with sarcoidosis. We go on to briefly discuss the action of daclizumab, in particular the effect 
it has on CD56
bright
 natural killer cells, a cell type that has been investigated in relation to 
sarcoidosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CASE DETAILS 
A 45-year old Caucasian male presented with a 2-month history of fevers, night sweats and 
non-productive cough. He had been on a series of consecutive trials of daclizumab for 
Relapsing Remitting Multiple Sclerosis (RRMS), totalling 79 months (12-months placebo-
controlled, 12-months dose-blinded, 55-months open-label of 150mg monthly 
subcutaneously).  He had experienced three relapses in the three years prior to commencing 
the trials but remained relapse-free during them. He had no significant co-morbidity. Physical 
examination revealed new bilateral inguinal lymphadenopathy. Neurological examination 
demonstrated longstanding altered left-sided facial sensation, mild instability on Romberg 
testing; Expanded Disability Status Scale (EDSS) score was stable at 2.0. Investigations 
revealed elevated ESR (35mm/hr), ACE (62 IU/L), IgG (27.65 g/L), IgM (5.51 g/L) and total 
protein (91 g/L) but were otherwise unremarkable (lymphocyte count 1.72 10^9 g/L, 
corrected-calcium 2.35 mmol/L). Daclizumab was suspended pending further investigation.  
CT-PET confirmed high avidity lymphadenopathy in the mediastinum and abdominal chains, 
but no visceral uptake (figure a). Lymph node aspirate obtained via endobronchial ultrasound 
demonstrated non-necrotising granulomatous inflammation (figure b). 
 
Brain MRI before/after gadolinium was stable with no new or enhancing lesions and no 
meningeal enhancement. Two months following daclizumab cessation, spirometry 
demonstrated moderate obstruction; FEV1 2.13 (62.3% predicted), FVC 3.62 (83.7% 
predicted), FEV1/FVC ratio 58.8%. At this point, all symptoms except the non-productive 
cough had resolved. No alternative aetiology was identified and a clinical diagnosis of 
sarcoidosis was made. Inhaled corticosteroids were commenced followed by a short trial of 
oral corticosteroids, both of which had no effect on the cough.   
 
CT-PET 6-months following daclizumab cessation demonstrated reduction in lymph node 
uptake. Repeat spirometry 10-weeks following discontinuation of corticosteroids was normal; 
FEV1 3.01 (88% predicted), FVC 3.74 (86.5% predicted), FEV1/FVC ratio 80.5%. 
Considering subjective and objective evidence of improvement following daclizumab 
cessation, it was reasoned that daclizumab was the probable cause and it was therefore 
permanently discontinued. 
 
DISCUSSION 
Sarcoidosis is a multi-system granulomatous disorder that most commonly affects the 
pulmonary and lymphatic systems. In most patients, granulomas resolve spontaneously or 
following appropriate therapy (e.g. corticosteroids with or without steroid sparing agents such 
as methotrexate). A minority of patients develop chronic progressive disease, characterised 
by persisting granulomas, which may undergo fibrosis, causing irreversible organ damage. 
Sarcoid granulomas are characterised by monocytes, macrophages and activated T cells, with 
interleukin-2 (IL-2) a driver cytokine of this Th1-type cellular response.
1
 
 
Daclizumab is a monoclonal antibody approved for treatment of RRMS. Trials have 
demonstrated its efficacy in reducing relapses, disability progression and development of new 
MRI lesions
2
. Daclizumab binds to the alpha chain (CD25) on high-affinity IL-2 receptors, 
inhibiting the association of IL-2 with the receptor. The IL-2 pathway is involved in 
activation, proliferation and differentiation of T cells and daclizumab is hypothesised to 
suppress IL-2-mediated T-cell expansion and activation
2
. The current understanding of 
sarcoid immunopathology makes its occurrence paradoxical in the setting of Daclizumab 
therapy. One speculative hypothesis lies in the effect of daclizumab on natural killer cells. 
CD56
bright
 cells are a subset of natural killer (NK) cells, observed in small numbers in 
peripheral blood but as a much greater proportion within lymph nodes
3
. These cells are 
immunoregulatory and have the capacity to produce a range of inflammatory cytokines (e.g. 
TNF-α, IFN-γ) when activated3. CD56bright NK cell populations expand significantly during 
daclizumab therapy. The proposed mechanism is that blockade of high-affinity IL-2 receptors 
leads to reduced IL-2 consumption as well as increased IL-2 production due to lack of 
negative feedback resulting in increased local availability of IL-2. CD56
bright
 NK cells express 
an intermediate-affinity IL-2 receptor. Daclizumab does not interact with this receptor 
allowing IL-2 to bind freely, resulting in cell proliferation
2
.  
 
Interestingly, higher numbers of CD56
bright
 cells have been observed in broncho-alveolar 
lavage fluid of individuals with sarcoidosis compared to controls
4
 and higher proportions of 
NK cells in this fluid have been found to correlate with a poor prognosis
5
. However, an 
expansion of CD56
bright
 cells can be seen in a range of diseases and it is unclear if they are a 
driver of disease or a consequence of the pathological process
3
. 
 
In a review of daclizumab, the Center for Drug Evaluation and Research (a division of the 
U.S. Food and Drug Administration), with access to raw trial data, identified nine cases of 
sarcoidosis amongst various RRMS trial cohorts, with another four potential cases. Based on 
these nine confirmed cases, the incidence of sarcoidosis was estimated to be approximately 
1.32/1,000 patient years compared to a reported rate in the general population of 1.0-35.5 per 
100,000/year
6
. One case of sarcoidosis has also been reported in a patient treated off study 
with another form of daclizumab in adult T-cell leukaemia/lymphoma
7
.  
 
The development of sarcoidosis has also been observed following the use of other disease 
modifying therapies. Several cases have been reported following the use of interferon-β, 
including specifically in patients being treated for multiple sclerosis
8
. There have also been 
reports of cases following the use of alemtuzumab
9
 and natalizumab
10
 in the treatment of 
other diseases; although to our knowledge, there are no reports in the literature of the 
development of sarcoidosis in patients treated with these medications for multiple sclerosis. 
This case emphasises the need to be vigilant for unexpected associations when using novel 
immunomodulatory therapies.  
 
 
 
Figure a - PET- CT demonstrating metabolically active mediastinal lymphadenopathy 
 
 Figure b - Cytology photomicrograph demonstrating granulomas following EBUS sampling 
 
Acknowledgements 
We would like to thank Dr Emma Mclean, consultant histopathologist at Guy’s and St 
Thomas’ Hospital for providing the cytology image. 
 
 
Consent 
The patient provided written consent for the details of this case to be published in an 
anonymised fashion. 
 
 
References 
 
1. Broos CE, van Nimwegen M, Hoogsteden HC, Hendriks RW, Kool M, Van den Blink B. 
Granuloma formation in pulmonary sarcoidosis. Front Immunol. 2013 Dec 10;4:437.  
 
2. Wiendl H, Gross CC. Modulation of IL-2Rα with daclizumab for treatment of multiple 
sclerosis. Nat Rev Neurol. 2013;9:394–404.  
 
3. Poli A, Michel T, Thérésine M, Andrès E, Hentges F, Zimmer J. CD56bright natural killer 
(NK) cells: an important NK cell subset. Immunology. 2009 Apr;126(4):458-465.  
 
4. Katchar K, Soderstrom K, Wahlstrom J, Eklund A, Grunewald J. Characterisation of 
natural killer cells and CD56+ T-cells in sarcoidosis patients. Eur Respir J. 2005 26(1):77-85.  
 
5. Tutor-Ureta P, Citores MJ, Castejón R, Mellor-Pita S, Yebra-Bango M, Romero Y, Vargas 
JA. Prognostic value of neutrophils and NK cells in bronchoalveolar lavage of sarcoidosis. 
Cytometry B Clin Cytom. 2006 Nov 15;70(6):416-422.  
 
6. Villalba, ML. Center for Drug Evaluation and Research medical review(s). Application 
Number 761029Orig1s000 Reference ID: 3906449 March 2016 
 
7. Berkowitz JL, Janik JE, Stewart DM, Jaffe ES, Stetler-Stevenson M, Shih JH, et al. Safety, 
efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients 
with adult T-cell leukemia/lymphoma. Clin Immunol. 2014 Dec;155(2):176-187.  
 
8. Sahraian MA, Moghadasi AN, Owji M, Maboudi M, Kosari F, McGee JC, Minagar A. 
Cutaneous and pulmonary sarcoidosis following treatment of multiple sclerosis with 
interferon-β-1b: a case report. J Med Case Rep. 2013 Dec 13;7:270.  
 
9. Thachil J, Jadhav V, Gautam M, McKew S, Arumainathan A, Collins D, et al. The 
development of sarcoidosis with the use of alemtuzumab - clues to T-cell immune 
reconstitution. Br J Haematol. 2007 Aug;138(4):559-60.  
 
10. Parisinos CA, Lees CW, Wallace WA, Satsangi J. Sarcoidosis complicating treatment 
with natalizumab for Crohn's disease. Thorax. 2011 Dec;66(12):1109-10.  
HIGHLIGHTS 
 Daclizumab is a relatively new disease modifying therapy for treatment of RRMS 
 A case of a 45 year old man developing sarcoidosis following daclizumab therapy 
 Current understanding of sarcoid immunopathology makes its occurrence paradoxical 
in the setting of Daclizumab therapy 
 Important to be vigilant for unexpected associations when using novel 
immunomodulatory therapies 
 
 
 
 
